Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hikal Limited ( (IN:HIKAL) ) just unveiled an update.
Hikal Limited has announced the appointment of Dr. Raghavendar Rao Morthala as the Head of CDMO R&T Pharma and Animal Health Business Unit, effective February 3, 2025. Dr. Morthala brings over 23 years of experience in the industry, having worked with notable organizations such as Dr. Reddy’s Laboratories and Syngene International. This strategic appointment is expected to strengthen Hikal’s position in the pharmaceutical and animal health industry, potentially enhancing their research and development capabilities and market competitiveness.
More about Hikal Limited
Hikal Limited operates in the pharmaceutical and animal health sectors, focusing on Contract Development and Manufacturing Organization (CDMO) services. The company is involved in pharmaceutical research and technology, providing solutions in areas such as process R&D, analytical R&D, and manufacturing.
YTD Price Performance: -11.83%
Average Trading Volume: 45,195
Current Market Cap: 43.83B INR
Find detailed analytics on HIKAL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue